Pulse Biosciences, Inc (PLSE) News
Filter PLSE News Items
PLSE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PLSE News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PLSE News From Around the Web
Below are the latest news stories about PULSE BIOSCIENCES INC that investors may wish to consider to help them evaluate PLSE as an investment opportunity.
Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive OfficerMIAMI, January 10, 2025--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer. |
Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare ConferenceMIAMI, January 03, 2025--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. |
Pulse Biosciences, Inc. Announces Planned Redemption of WarrantsHAYWARD, Calif., December 23, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about December 27, 2024, to redeem the first tranche of common stock warrants, redeemable by the Company if the Company’s stock trading price exceeds $16.50 for twenty consecutive trading days, that were issued as part of it |
Pulse Biosciences, Inc. Announces Election to Exercise Company WarrantsHAYWARD, Calif., December 19, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that, on December 18, 2024, the Company’s Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants he acquired in the Company’s 2024 rights offering, corresponding to $58.4 million totaling to 5,306,156 shares of C |
Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular SurgeryMIAMI, December 17, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a new publication in the Journal of Thoracic and Cardiovascular Surgery. This preclinical study demonstrates the advantages of the nano-PFA Cardiac Surgical System over radiofrequency technology for the ablation of cardiac tissue. |
Robert Duggan Spends US$972k On Pulse Biosciences StockThose following along with Pulse Biosciences, Inc. ( NASDAQ:PLSE ) will no doubt be intrigued by the recent purchase of... |
Top Key Executive Robert Duggan, Pulse Biosciences, Inc.'s (NASDAQ:PLSE) largest shareholder sees value of holdings go down 13% after recent dropKey Insights Pulse Biosciences' significant insider ownership suggests inherent interests in company's expansion 69% of... |
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, Pulse Biosciences... |
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid AssociationMIAMI, October 31, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation for the treatment of benign thyroid nodules. Dr. Stefano Spiezia presented these excellent results today at the 2024 American Thyroid Association Annual Meeting. |
Q3 2024 Pulse Biosciences Inc Earnings CallQ3 2024 Pulse Biosciences Inc Earnings Call |